Duloxetine: pharmacoeconomic implications of an antidepressant that alleviates painful physical symptoms

Bibliography

• DEMYTTENAERE K, BRUFFAERTS R, POSADA-VILLA J et al: Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA (2004) 291:2581–2590.
   PubMed Web of Science ®Google Scholar
• •Pivotal study describing the global burden of depressive illness.
   Google Scholar
• LEPINE JP, GASTPAR M, MENDLEWICZ J, TYLEE A: Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int. Clin. Psychepharmacel (1997) 12:19–29.
   PubMed Web of Science ®Google Scholar
• WARAICH P, GOLDNER EM, SOMERS JM, HSU L: Prevalence and incidence studies of mood disorders: a systematic review of the literature. Can. .1 Psychiatry (2004) 49:124–138.
   PubMed Web of Science ®Google Scholar
• AMERICAN PSYCHIATRIC ASSOCIATION: Diagnostic and Statistical Manual of Mental Disorders: American Psychiatric Press, Inc., Washington DC (1994).
   Google Scholar
• KATON W, SCHULBERG H: Epidemiology of depression in primary care. Gen. Hasp. Psychiatry (1992) 14:237–247.
   PubMed Web of Science ®Google Scholar
• KESSLER RC, MCGONAGLE KA, ZHAO S et al: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry (1994) 51:8–19.
   PubMed Web of Science ®Google Scholar
• KENDLER KS: Hierarchy and heritability: the role of diagnosis and modeling in psychiatric genetics. Am. I Psychiatry (2002) 159:515–518.
   PubMed Web of Science ®Google Scholar
• KENDLER KS, GARDNER CO, PRESCOTT CA: Toward a comprehensive developmental model for major depression in women. Am. I Psychiatry (2002) 159:1133–1145.
   PubMed Web of Science ®Google Scholar
• BERTO P, D'ILARIO D, RUFFO P, DI VR, RIZZO F: Depression: cost-of-illness studies in the international literature, a review. ./. Ment. Health Policy Econ. (2000) 3:3–10.
   PubMedGoogle Scholar
• MCINTYRE RS, O'DONOVAN C: The human cost of not achieving full remission in depression. Can. .1 Psychiatry (2004) 49:10S–16S.
   Google Scholar
• ••Comprehensive modelling of thepathogenesis of MDD.
   Google Scholar
• GREENBERG PE, STIGLIN LE, FINKELSTEIN SN, BERNDT ER: The economic burden of depression in 1990. J. Chit. Psychiatry (1993) 54:405–418.
   PubMed Web of Science ®Google Scholar
• MURRAY CJ, LOPEZ AD: Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet (1997) 349:1436–1442.
   PubMed Web of Science ®Google Scholar
• KESSLER RC, BERGLUND P, DEMLER O et al: The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA (2003) 289:3095–3105.
   PubMed Web of Science ®Google Scholar
• GOLDENBERG DL, BURCKHARDT C, CROFFORD L: Management of fibromyalgia syndrome. "AMA (2004) 292:2388–2395.
   PubMed Web of Science ®Google Scholar
• MENDELL JR, SAHENK Z: Clinical practice. Painful sensory neuropathy. N Engl. J. Med. (2003) 348:1243–1255.
   PubMed Web of Science ®Google Scholar
• KRISHNAN Si RAYMAN G: New treatments for diabetic neuropathy: symptomatic treatments. Curr. Blab. Rep. (2003) 3:459–467.
   PubMedGoogle Scholar
• STAHL SM, ZHANG L, DAMATARCA C, GRADY M: Brain circuits determine destiny in depression: a novel approach to the psychopharmacology of wakefulness, fatigue, and executive dysfunction in major depressive disorder. Clin. Psychiatry (2003) 64\(Suppl. 14):6–17.
   Google Scholar
• OHAYON MM, SCHATZBERG AF: Using chronic pain to predict depressive morbidity in the general population. Arch. Gen. Psychiatry (2003) 60:39–47.
   PubMed Web of Science ®Google Scholar
• JACKSON JL, HOUSTON JS, HANLING SR, TERHAAR KA, YUN JS: Clinical predictors of mental disorders among medical outpatients. Arch. Intern. Med. (2001) 161:875–879.
   PubMed Web of Science ®Google Scholar
• KATON W, SULLIVAN M, WALKER E: Medical symptoms without identified pathology: relationship to psychiatric disorders, childhood and adult trauma, and personality traits. Ann. Intern. Med. (2001) 134:917–925.
   PubMed Web of Science ®Google Scholar
• KROENKE K, SPITZER RL, WILLIAMS JB et al.: Physical symptoms in primary care. Predictors of psychiatric disorders and functional impairment. Arch. Fain. Med. (1994) 3:774–779.
   PubMedGoogle Scholar
• SIMON GE, VONKORFF M: Somatization and psychiatric disorder in the NIMH Epidemiologic Catchment Area study. Ain. J. Psychiatry (1991) 148:1494–1500.
   PubMed Web of Science ®Google Scholar
• GERBER PD, BARRETT J, BARRETT J,MANHEIMER E, WHITING R, SMITH R: Recognition of depression by internists in primary care: a comparison of internist and 'gold standard' psychiatric assessments. .1 Gen Intern. Med. (1989) 4:7–13.
   Google Scholar
• KATON W: Depression: relationship to somatization and chronic medical illness. Clin. Psychiatry (1984) 45:4–12.
   PubMed Web of Science ®Google Scholar
• GERBER PD, BARRETT JE, BARRETT JA et al: The relationship of presenting physical complaints to depressive symptoms in primary care patients. J Gen. Intern. Med. (1992) 7:170–173.
   PubMed Web of Science ®Google Scholar
• PAPAKOSTAS GI, PETERSEN T, HUGHES ME, NIERENBERG AA, ALPERT JE, FAVA M: Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder. Psychiatry Res. (2004) 126:287–290.
   PubMed Web of Science ®Google Scholar
• BASBAUM Al, FIELDS HL: Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Ann. Rev NeuroscL (1984) 7:309–338.
   PubMed Web of Science ®Google Scholar
• ••Perspective paper describing howoutcomes should be measured in depressive disorders.
   Google Scholar
• JONES SL: Descending noradrenergic influences on pain. Frog. Brain Res. (1991) 88:381–394.
   PubMed Web of Science ®Google Scholar
• RICHARDSON BP: Serotonin and nociception. Ann. NY Acad. Sci. (1990) 600:511–519.
   PubMed Web of Science ®Google Scholar
• KELLER MB: Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. "AMA (2003) 289:3152–3160.
   PubMed Web of Science ®Google Scholar
• GEDDES JR, CARNEY SM, DAVIES C et al: Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet (2003) 361:653–661.
   PubMed Web of Science ®Google Scholar
• ••Underscores the pernicious nature ofsubsyndromal symptoms.
   Google Scholar
• JUDD LL, AKISKAL HS, MASER JD et al: Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J. Affect. Disord. (1998) 50:97–108.
   PubMed Web of Science ®Google Scholar
• JUDD LL, AKISKAL HS, MASER JD et al: A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch. Gen. Psychiatry (1998) 55:694–700.
   PubMed Web of Science ®Google Scholar
• JUDD LL, PAULUS MJ, SCHETTLER PJ et al: Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Ain. J. Psychiatry (2000) 157:1501–1504.
   Google Scholar
• KELLER MB: Remission versus response:the new gold standard of antidepressant care. J. Clin. Psychiatry (2004) 65\(Suppl. 4):53–59.
   Google Scholar
• THASE ME, ENTSUAH AR, RUDOLPH RL: Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. BE J. Psychiatry (2001) 178:234–241.
   PubMed Web of Science ®Google Scholar
• KENNEDY SH, LAM RW, COHEN NL, RAVINDRAN AV: Clinical guidelines for the treatment of depressive disorders. IV Medications and other biological treatments. Can. J. Psychiatry (2001) 46\(Suppl. 1):38S–58S.
   Google Scholar
• SMITH D, DEMPSTER C, GLANVILLE J, FREEMANTLE N, ANDERSON I: Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. BE J. Psychiatry (2002) 180:396–404.
   PubMed Web of Science ®Google Scholar
• FREEMANTLE N, ANDERSON IM, YOUNG P: Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Meta-regression analysis. BE J. Psychiatry (2000) 177:292–302.
   PubMed Web of Science ®Google Scholar
• SHELTON RC: The dual-action hypothesis: does pharmacology matter? I Clin. Psychiatry (2004) 65\(Suppl. 17):5–10.
   Google Scholar
• THASE ME: Introduction: the dual-actiondebate: does pharmacology matter?' Clin. Psychiatry (2004) 65\(Suppl. 17)3–4.
   Google Scholar
• DANISH UNIVERSITY ANTIDEPRESSANT GROUP (DUAG): Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Danish University Antidepressant Group. Psychopharmacology (Berl) (1986) 90:131–138.
   PubMed Web of Science ®Google Scholar
• DANISH UNIVERSITY ANTIDEPRESSANT GROUP (DUAG): Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group. I Affect. Disord. (1990) 18:289–299.
   PubMed Web of Science ®Google Scholar
• ENTSUAH AR, HUANG H, THASE ME: Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. Clin. Psychiatry (2001) 62:869–877.
   PubMed Web of Science ®Google Scholar
• WONG DT, BYMASTER FP, MAYLE DA, REID LR, KRUSHINSKI JH, ROBERTSON DW: LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology (1993) 8:23–33.
   PubMed Web of Science ®Google Scholar
• LANTZ RJ, GILLESPIE TA, RASH TJ et al: Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab. Dispos. (2003) 31:1142–1150.
   PubMed Web of Science ®Google Scholar
• SKINNER MH, KUAN HY, PAN A et a/.: Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin. Pharmacol Ther. (2003) 73:170–177.
   Google Scholar
• •Describes synergistic relationship between depression scores and pain alleviation.
   Google Scholar
• VAN KERREBROECK P, ABRAMS P, LANGE R et al: Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. BIOC (2004) 111:249–257.
   Google Scholar
• GOLDSTEIN DJ, MALLINCKRODT C, LU Y, DEMITRACK MA: Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. I. Clin. Psychiatry (2002) 63:225–231.
   PubMed Web of Science ®Google Scholar
• DETKE MJ, WILTSE CG, MALLINCKRODT CH, MCNAMARA RK, DEMITRACK MA, BITTER I: Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur. Neuropsychopharmacol. (2004) 14:457–470.
   PubMed Web of Science ®Google Scholar
• DETKE MJ, LU Y, GOLDSTEIN DJ, HAYES JR, DEMITRACK MA: Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J. Clin. Psychiatry (2002) 63:308–315.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN DJ, LU Y, DETKE MJ, HUDSON J, IYENGAR S, DEMITRACK MA: Effects of duloxetine on painful physical symptoms associated with depression. Psychosomatics (2004) 45:17–28.
   PubMed Web of Science ®Google Scholar
• FAVA M, MALLINCKRODT CH, DETKE MJ, WATKIN JG, WOHLREICH MM: The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates?' Clin. Psychiatry (2004) 65:521–530.
   Google Scholar
• FRITZSCHE K, SANDHOLZER H, BRUCKS U et al.: Psychosocial care by general practitioners - where are the problems? Results of a demonstration project on quality management in psychosocial primary care. Int. j Psychiatry Med. (1999) 29:395–409.
   PubMed Web of Science ®Google Scholar
• KATON WJ: Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol. Psychiatry (2003) 54:216–226.
   PubMed Web of Science ®Google Scholar
• THOMPSON D: Toward a pharmacoeconomic model of neuropathic pain. Clin. J. Pain (2002) 18:366–372.
   PubMed Web of Science ®Google Scholar
• SOLBERG LI, HURLEY JS, ROBERTS MH et al: Measuring patient safety in ambulatory care: potential for identifying medical group drug-drug interaction rates using claims data. Am. J. Manag. Care (2004) 10:753–759.
   PubMed Web of Science ®Google Scholar
• MCINTYRE RS, KONARSKI JZ, YATHAM LN: Comorbidity in bipolar disorder: a framework for rational treatment selection. Human Psychopharmacology (2004) 19:369–386.
   PubMed Web of Science ®Google Scholar
• ROWBOTHAM MC, GOLI V, KUNZ NR, LEI D: Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain (2004) 110:697–706.
   PubMed Web of Science ®Google Scholar
• FORSSELL H, TASMUTH T, TENOVUO O, HAMPF G, KALSO E: Venlafaxine in the treatment of atypical facial pain: a randomized controlled trial. J. Draw. Pain (2004) 18:131–137.
   Web of Science ®Google Scholar
• REUBEN SS, MAKARI-JUDSON G, LURIE SD: Evaluation of efficacy of the perioperative administration of venlafaxine XR in the prevention of postmastectomy pain syndrome. J. Pain Symptom Manage. (2004) 27:133–139.
   PubMed Web of Science ®Google Scholar
• SINDRUP SH, BACH FW, MADSEN C, GRAM LF, JENSEN TS: Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology (2003) 60:1284–1289.
   PubMed Web of Science ®Google Scholar
• BENDTSEN L, JENSEN R: Mirtazapine iseffective in the prophylactic treatment of chronic tension-type headache. Neurology (2004) 62:1706–1711.
   PubMed Web of Science ®Google Scholar
• BYMASTER FP, DRESHFIELD-AHMAD LJ et al.: Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology (2001) 25:871–880.
   PubMed Web of Science ®Google Scholar
• TATSUMI M, GROSHAN K, BLAKELY RD, RICHELSON E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur. Pharmacol (1997) 340:249–258.
   PubMed Web of Science ®Google Scholar